Rick Gonzalez’s Legacy and AbbVie’s Future under Robert Michael
February 20, 2024
Rick Gonzalez, CEO of AbbVie, transformed Humira into the world’s top-selling drug, defying politics and competition. As he prepares to retire in July, his successor, Robert Michael, AbbVie’s current president and COO, will inherit a thriving company poised for future growth. Michael’s internal promotion contrasts with other pharmaceutical companies’ trend of seeking external leadership for revitalization. Despite facing challenges like Humira biosimilars and declining sales, AbbVie projects strong revenue growth buoyed by promising Skyrizi and Rinvoq drugs and strategic acquisitions like ImmunoGen and Cerevel Therapeutics. Gonzalez’s tenure is marked by strategic patents and deals that secured AbbVie’s market dominance and prepared it for a future beyond Humira.
To read more, click here.
[Source: Endpoints, February 20th, 2024]
